Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials

Almuhammadi GA., Alhabeeb SW., Alharbi RB., Yamani MH., Alzughaibi RA., Mufti BM.

Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Syst Rev (2026)
Reported sample size
3345
Source database
Europe PMC
PMID
41851860
PMCID
PMC13112975
DOI
10.1186/s13643-026-03133-w

Abstract (original English)

Background/objectives Cardiovascular diseases (CVDs), particularly myocardial infarction (MI) and heart failure (HF), remain global causes of morbidity and mortality, despite the current treatment options. Stem cell therapy (SCT) has emerged as a promising intervention aimed at halting disease progression and promoting cardiac repair. Nonetheless, the clinical efficacy, optimal cell type, delivery method, and safety profile of SCT remain inadequately defined. Methods This systematic review and meta-analysis aimed to evaluate the efficacy and safety of SCT in patients diagnosed with ischemic heart disease (IHD) and HF. PubMed, Web of Science, Embase, Scopus, and Science Direct were searched to retrieve randomized controlled trials (RCTs) investigating SCT in patients with MI or HF. Primary outcomes encompassed changes in left ventricular ejection fraction (LVEF), end-diastolic and end-systolic volumes (LVEDV, LVESV), infarct size, functional status, and quality of life measures. Risk ratios were calculated for safety outcomes. Subgroup analyses were executed based on follow-up duration, delivery method, and type of stem cell utilized. Results This review included 35 RCTs comprising 3345 patients (1875 in the SCT group and 1488 in the control group). The SCT indicated that significantly enhanced LVEF at 3, 6, and 12 months (mean difference [MD] = 1.43; 95% CI 0.92 to 1.95; p Conc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansMyocardial InfarctionStroke VolumeTreatment OutcomeStem Cell TransplantationQuality of LifeHeart FailureRandomized Controlled Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research